Bivirkningerne er kun anført, hvis de er set ud over dem, set med Xeloda- monoterapi eller set i en højere frekvensgruppe sammenlignet med Xeloda- monoterapi (se tabel 4).
ADRs are added to the appropriate frequency grouping (Very common or Common) according to the highest incidence seen in any of the major clinical trials and are only added when they were seen in addition to those seen with Xeloda monotherapy or seen at a higher frequency grouping compared to Xeloda monotherapy (see Table 4).